This report highlights the urgent need for Europe to strengthen its biopharma industry to maintain global competitiveness and ensure health security. ​ It identifies challenges such as regulatory fragmentation, insufficient R&D funding, and the exodus of SMEs, while proposing solutions like creating innovation hubs, simplifying regulations, and enhancing public-private collaboration. ​ The recommendations emphasize prioritizing biopharma as a strategic sector, fostering resilience in supply chains, and adopting balanced policies to support innovation and sustainability. ​